The broadest impact comes from immune checkpoint blockade (ICB) that reinvigorates anti-tumor cytotoxic T lymphocytes (CTLs) using antibodies against CTLA4 or PD1/PD-L1 and generates therapeutic responses across a variety of cancer types (1). This evidence concerns the gene CD274 and neoplasm.